74 completed, 29 unknown, 15 terminated, 14 withdrawn. 135 Phase 1, 57 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 135 | Completed 74, Unknown 29, Terminated 15, Withdrawn 14, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 57 | Completed 28, Unknown 13, Withdrawn 9, Terminated 5, Recruiting 2 |
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19 | Phase 1 | Not yet recruiting | AVM Biotechnology Inc | 16 | 2026-12-01 | 2025-10-02 |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 | |
| The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8) - Covid19, Novel Coronavirus Pneumonia | Phase 1 / Phase 2 | Unknown | AVEM HealthCare | 55 | 2023-09-01 | 2022-03-11 |
| Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) sotrovimab - Covid19 | Phase 1 | Terminated | Vir Biotechnology, Inc. | 316 | 2022-03-28 | 2024-09-19 |
| Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults SII B.1.351, SII Bivalent, SII B.1.617.2 - Covid19 | Phase 1 / Phase 2 | Withdrawn | Novavax | 2022-02-04 | 2022-05-31 | |
| Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients Angiotensin-(1-7), Placebo - Covid19 | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2022-02-01 | 2022-03-03 | |
| Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine - Covid19 | Phase 1 | Completed | PT Bio Farma | 54 | 2021-12-10 | 2022-08-09 |
| COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines hAd5-S-Fusion+N-ETSD vaccine - Covid19 | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2021-12-01 | 2025-02-21 | |
| Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection MPT0B640 - Covid19 | Phase 1 | Withdrawn | J Ints Bio | 2021-12-01 | 2021-06-11 | |
| Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19 Allocetra-OTS - Covid19 | Phase 1 | Unknown | Enlivex Therapeutics Ltd. | 18 | 2021-12-01 | 2021-08-18 |
| COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines hAd5-S-Fusion+N-ETSD vaccine - Covid19 | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2021-12-01 | 2025-02-21 | |
| A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 SARS-CoV-2 DNA Vaccine, Matching placebo - Covid19 | Phase 1 | Unknown | The University of Hong Kong | 30 | 2021-11-18 | 2022-01-27 |
| GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19) GLS-5130, Placebo - Covid19, Healthy | Phase 1 | Unknown | GeneOne Life Science, Inc. | 30 | 2021-11-01 | 2021-10-20 |
| Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized A vaccine composed of a recombinant S1 antigen - Covid19 | Phase 1 / Phase 2 | Withdrawn | Hospital do Coracao | 2021-11-01 | 2021-08-27 | |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 Angiotensin Converting Enzyme 2, Sodium chloride - Covid19 | Phase 1 | Completed | Apeiron Biologics | 40 | 2021-10-19 | 2022-09-23 |
| A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222 - Covid19, SARS-CoV-2 Infection | Phase 1 | Unknown | Imperial College London | 28 | 2021-10-10 | 2023-09-06 |
| Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Smell Retraining, Budesonide - Dysosmia, Anosmia | Phase 1 / Phase 2 | Terminated | Amanda Stapleton | 20 | 2021-09-30 | 2024-06-13 |
| SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease Standard of Care, SARS-CoV2-CTLS - Covid19 | Phase 1 / Phase 2 | Recruiting | New York Medical College | 50 | 2021-09-20 | 2026-04-13 |
| Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection Cytotoxic T Lymphocytes - Covid19 | Phase 1 | Completed | Thomas Jefferson University | 30 | 2021-09-15 | 2025-04-29 |
| Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers AdCLD-CoV19-1 - Covid19 | Phase 1 | Completed | Cellid Co., Ltd. | 40 | 2021-09-09 | 2023-07-28 |
Showing 20 of 135. Sign in to see all of them.
COVID-19 (135) · Coronavirus Infections (17) · Respiratory Distress Syndrome (10) · Severe Acute Respiratory Syndrome (10) · Pneumonia (5) · Pulmonary Fibrosis (3) · Cytokine Release Syndrome (2) · Pneumonia, Viral (2) · Acute Lung Injury (1) · Anosmia (1) · Cognitive Dysfunction (1) · Communicable Diseases (1) · Dyspnea (1) · Inflammation (1) · Influenza, Human (1)
Coronaviridae Infections (135) · Infections (135) · Lung Diseases (135) · Nidovirales Infections (135) · RNA Virus Infections (135) · Respiratory Tract Diseases (135) · Respiratory Tract Infections (135) · Virus Diseases (135) · Pneumonia, Viral (133) · Pneumonia (130) · Coronavirus Infections (118) · Pathological Conditions, Signs and Symptoms (11) · Respiration Disorders (11) · Pathologic Processes (9) · Fibrosis (3)
Standard of Care (6) · Ivermectin (4) · sotrovimab (3) · Ribavirin (2) · Ritonavir (2) · STI-2020 (2) · Single Person (2) · Sodium Chloride (2) · aspartyl-alanyl-diketopiperazine (2) · favipiravir (2) · remdesivir (2) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · ABNCoV2 vaccine (1) · AKS-452 COVID-19 vaccine (1) · Acetylcysteine (1)
ImmunityBio, Inc. (4) · Sorrento Therapeutics, Inc. (3) · Stanford University (3) · The University of Hong Kong (3) · Ampio Pharmaceuticals. Inc. (2) · Bausch Health Americas, Inc. (2) · D'Or Institute for Research and Education (2) · Imperial College London (2) · Novavax (2) · Research Institute for Biological Safety Problems (2) · University Medical Center Groningen (2) · Universitätsklinikum Hamburg-Eppendorf (2) · Vir Biotechnology, Inc. (2) · AVEM HealthCare (1) · AVM Biotechnology Inc (1)
United States (39) · Australia (7) · Israel (6) · Brazil (5) · Russia (5) · United Kingdom (5) · Canada (4) · Mexico (4) · China (3) · Germany (3) · Hong Kong (3) · Indonesia (3) · Netherlands (3) · South Korea (3) · Turkey (Türkiye) (3)
Anya Loncaric (2) · Ivan Fan-ngai Hung (2) · Marylyn M Addo, MD (2) · Mike Royal, MD (2) · Aldar Bourinbayar, MD/PhD (1) · Ali Dehghan-Manshadi, MD (1) · Amanda L Stapleton, MD (1) · Ashish Patel, PhD FRCS (1) · Barry Bratcher (1) · Berik Khairullin, PhD (1) · Bijan Modarai, PhD FRCS (1) · Bill Arana (1) · Catherine H Marshall, MD/MPH (1)
PMID 34473343, PMID 31986264, PMID 36435633, PMID 39749328, PMID 10415784, PMID 12563677, PMID 14719037, PMID 15663512, PMID 17181919, PMID 18097874, PMID 19397687, PMID 19453649, PMID 19998041, PMID 21131395, PMID 22028728, PMID 22545014, PMID 22731679, PMID 26867177, PMID 27344959, PMID 28584818, PMID 30473697, PMID 32007143, PMID 32035018, PMID 32071063, PMID 32089354, PMID 32109013, PMID 32112977, PMID 32113509, PMID 32122636, PMID 32125455, PMID 32159775, PMID 32192578, PMID 32203186, PMID 32211963, PMID 32234467, PMID 32251768, PMID 32257537, PMID 32278362, PMID 32283152, PMID 32360286, PMID 32396163, PMID 32423449, PMID 32555388, PMID 32653469, PMID 33568226, PMID 33845867, PMID 33887208, PMID 34306677, PMID 34346827, PMID 34414368
R44HL158446 (1)